Do guidelines for the prescribing and monitoring of leflunomide need to be modified? [2]

Rheumatology

Volumn 43, Issue 11, 2004, Pages 1447-1448

  Rajakulendran, S ^a   Deighton, Chris ^a,b  

^a DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^b Department of Rheumatology ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ANTIRHEUMATIC AGENT; COLESTYRAMINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

DRUG ALCOHOL INTERACTION; DRUG CHOICE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; MEDICAL PRACTICE; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATIC DISEASE; TREATMENT FAILURE;

ANTIRHEUMATIC AGENTS; DRUG MONITORING; ENGLAND; HUMANS; ISOXAZOLES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG;

EID: 8344278019     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh359     Document Type: Letter

References (13)

1. Arava Summary of Product Characteristics. Aventis Pharmaceuticals, July 2002.
2. Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology 2004;43:206-10.
3. British Society for Rheumatology. National guidelines for the monitoring of second line drugs (online), July 2000. http://www.msecportal.org/portal/editorial/PublicPages/bsr/ 536883013/3.doc
4. Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
5. Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-36.
6. The European Agency for the Evaluation of Medicinal Products. Post-authorisation evaluation of medicines for human use. EMEA public statement on leflunomide (Arava) - severe and serious hepatic reactions. Document reference EMEA/H/5611/01/en. London, 12 March 2001.
7. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Int Med 1999;159:2542-50.
8. Smolen JS, Kalden JR, Scott DL et al. and the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind randomised multicentre trial. Lancet 1999;353:259-66.
9. Emery P, Breedfeld C, Lemmel EM et al. and the multinational leflunomide study group. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.
10. Cohen S, Cannon GW, Schiff M et al. Two-year blinded randomized controlled treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984-92.
11. Scott DL, Smolen JS, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
12. Kalden JR, Schattenkirchner M, Sorensen H et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow up study. Arthritis Rheum 2003;48: 1513-20.
13. Sinha A, Amos N, Lawson TM. Leflunomide - the Welsh experience. Rheumatology 2003;42(Suppl. 1):97-8.